Julie Rubinstein, President and Chief Operating Officer of Adaptive Biotechnologies Corp (NASDAQ: ADPT), completed a series of transactions involving company stock between March 27 and March 31, 2026. Over that period Rubinstein sold a total of 57,180 shares of common stock at prices spanning $12.07 to $13.87, producing aggregate proceeds of approximately $751,302.
Those sales followed the exercise of stock options. Rubinstein exercised options to acquire 44,166 shares of Adaptive Biotechnologies common stock at an exercise price of $7.27 per share, representing a total cost of $321,086 to obtain those shares.
The trades occurred while the stock was trading near $13.88 and amid notable share-price volatility. InvestingPro data cited in company reporting indicates the stock has delivered an 86.81% return over the past year despite displaying recent weakness.
According to the SEC filings, the transactions were conducted pursuant to a pre-arranged Rule 10b5-1 trading plan that Rubinstein adopted on November 18, 2025. After the option exercises and subsequent sales, Rubinstein directly holds 455,878 shares of Adaptive Biotechnologies.
Operational and analyst context
Adaptive Biotechnologies also reported fourth-quarter 2025 financial results that outperformed analyst expectations. The company posted adjusted earnings per share of -$0.09, versus a consensus forecast of -$0.18, a 50% positive surprise relative to the estimate. Revenue for the quarter came in at $71.7 million, topping the projected $59.33 million by 20.85%.
Following the quarterly release and related guidance, several sell-side firms adjusted their views. BTIG raised its price target on Adaptive Biotechnologies to $22.00 from $21.00 while maintaining a Buy rating, citing growth in the company’s Minimal Residual Disease business. TD Cowen increased its price target to $21.00 from $20.00 following the pre-announced results and guidance. Piper Sandler reiterated an Overweight rating and retained a $20.00 price target, also highlighting the company’s position in the minimal residual disease market.
Separately, InvestingPro’s Fair Value analysis cited in reporting indicates the company currently appears overvalued and notes that analysts are not forecasting profitability for the company this year. For those seeking additional research, a comprehensive Pro Research Report covering ADPT and more than 1,400 other U.S. equities is available through InvestingPro.
Contextual note
The transactions by a senior executive, the use of a Rule 10b5-1 trading plan, recent option exercises, and the company’s latest quarterly results together present a multifaceted snapshot of insider activity and firm performance. The SEC disclosures provide the concrete transaction data; the company's reported quarterly performance and subsequent analyst reactions offer further market context for investors and observers.